Updates of the drugs of the Brazilian Obesity Guideline: a literature review

Authors

DOI:

https://doi.org/10.33448/rsd-v11i4.27139

Keywords:

Obesity; Sibutramine; Orlistat; Liraglutide.

Abstract

Objective: to update data on the three drugs recommended in the Brazilian Obesity Guideline (2016) – sibutramine, orlistat and liraglutide – gathering new evidence produced in the last 5 years. Methodology: A literature review was performed using the PubMed, Scopus and Embase databases, including studies published between 2017 and 2021, without language restriction. Results: In total, 21 studies were included, which brought new evidence on sibutramine, orlistat and liraglutide. Final considerations: Sibutramine proved to be safe and effective in obese patients with low cardiovascular risk, orlistat has relevant results in the treatment of polycystic ovary syndrome and non-alcoholic fatty liver, but it still has unpleasant adverse reactions and liraglutide shows up promising, causing consistent weight loss and few adverse effects. On the other hand, new clinical trials, systematic reviews and meta-analysis are needed to raise new evidence of efficacy and safety on the topic.

References

Al-Tahami, B. A. M., Ismail, A. A. A. -., Sanip, Z., Yusoff, Z., Shihabudin, T. M. T. M., Singh, T. S. P., & Rasool, A. H. G. (2017). Metabolic and inflammatory changes with orlistat and sibutramine treatment in obese malaysian subjects. Journal of Nippon Medical School, 84(3), 125-132. doi:10.1272/jnms.84.125

Alvarez-Leite, J. I., Soares, F. L. P., & Teixeira, L. G. (2016). Controle Neuroendócrino da Saciedade. Sistema Digestório: Integração Básico-Clínica, November, 389–410. https://doi.org/10.5151/9788580391893-16

Associação Brasileira para Estudo da Obesidade e Sobrepeso (ABESO). (2020, February 26). Obesidade e sobrepeso. ABESO. Retrieved January 10, 2022, from https://abeso.org.br/conceitos/obesidade-e-sobrepeso/

Associação Brasileira para Estudo da Obesidade. (2016). Diretrizes brasileiras de obesidade 2016. VI Diretrizes Brasileiras de Obesidade, 7–186. https://abeso.org.br/wp-content/uploads/2019/12/Diretrizes-Download-Diretrizes-Brasileiras-de-Obesidade-2016.pdf

Biblioteca Prof. Paulo de Carvalho Mattos. Tipos de revisão de literatura. Universidade Estadual de São Paulo (UNESP). 2015. Retrieved February, 26, 2022, from https://www.fca.unesp.br/Home/Biblioteca/tipos-de-evisao-de-literatura.

Caroline Maliska Klauck, G. Â. G. Z., & Débora Regina Hendges Poletto Pappen, N. R. T. B. (2019). Comorbidades associadas à obesidade em pacientes candidatos à cirurgia bariátrica. Revista Brasileira de Obesidade, Nutrição e Emagrecimento, 2(12), 588–596.

Caterson, I. D., Finer, N., Coutinho, W., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Legler, U. F., Shepherd, G. M., Rode, R. A., Perdok, R. J., Renz, C. L., James, W. P., & SCOUT Investigators (2012). Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes, obesity & metabolism, 14(6), 523–530. https://doi.org/10.1111/j.1463-1326.2011.01554.x

Coutinho W. (2009). The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arquivos brasileiros de endocrinologia e metabologia, 53(2), 262–270. https://doi.org/10.1590/s0004-27302009000200018

Dedov, I.I., Melnichenko, G. A., Troshina, E. A., Mazurina, N. V., & Galieva, M. O. (2018). Redução de Peso Corporal Associada ao Tratamento de Sibutramina: Resultados Gerais do Ensaio de Atenção Primária à Saúde da PRIMAVERA. Obesity Facts, 11(4), 335-343. https://doi.org/10.1159/000488880

Esmail, V. A. W., Mohammed, M. O., & Al-Nimer, M. S. M. (2021). Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab Journal of Gastroenterology, 22(1), 1–5. https://doi.org/10.1016/j.ajg.2020.12.005

Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020). Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes care, 43(5), 1085–1093. https://doi.org/10.2337/dc19-1745

Grilo, C. M., White, M. A., Ivezaj, V., & Gueorguieva, R. (2020). Randomized controlled trial of behavioral weight loss and stepped care for binge-eating disorder: 12-month follow-up. Obesity, 28(11), 2116-2124. doi:10.1002/oby.22975

Holmbäck, U., Forslund, A., Grudén, S., Alderborn, G., Söderhäll, A., Hellström, P. M., & Lennernäs, H. (2020). Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obesity Science and Practice, 6(3), 313–323. https://doi.org/10.1002/osp4.405

James, W. P., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H., & Van Gaal, L. F. (2000). Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet (London, England), 356(9248), 2119–2125. https://doi.org/10.1016/s0140-6736(00)03491-7

Kadouh, H., Chedid, V., Halawi, H., Burton, D. D., Clark, M. M., Khemani, D., Vella, A., Acosta, A., & Camilleri, M. (2020). GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. The Journal of clinical endocrinology and metabolism, 105(5), 1552–1563. https://doi.org/10.1210/clinem/dgz140

Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., Arslanian, S., & NN8022-4180 Trial Investigators (2020). A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. The New England journal of medicine, 382(22), 2117–2128. https://doi.org/10.1056/NEJMoa1916038

Kristensen, M., Juul, S. R., Sørensen, K. V, Lorenzen, J. K., & Astrup, A. (2017). Supplementation with dairy calcium and/or flaxseed fibers in conjunction with orlistat augments fecal fat excretion without altering ratings of gastrointestinal comfort. Nutrition and Metabolism, 14(1), 1–11. https://doi.org/10.1186/s12986-017-0164-8

Larsen, J. R., Vedtofte, L., Jakobsen, M., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., Nielsen, J., Holst, J. J., Ekstrøm, C. T., Correll, C. U., Vilsbøll, T., & Fink-Jensen, A. (2017). Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA psychiatry, 74(7), 719–728. https://doi.org/10.1001/jamapsychiatry.2017.1220

le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D., Van Gaal, L., Ortiz, R. V., Wilding, J., Skjøth, T. V., Manning, L. S., Pi-Sunyer, X., & SCALE Obesity Prediabetes NN8022-1839 Study Group (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet (London, England), 389(10077), 1399–1409. https://doi.org/10.1016/S0140-6736(17)30069-7

Logvinova, O., Kuznetsova, P., Tsvetkova, E., Kremneva, E., Troshina, E., Romantsova, T., Tanashyan, M., & Kolpakova, E. (2020). Study of the effect of sibutramine on central mechanisms of regulation of eating behavior in patients with obesity by means of fMRI. Preliminary results. 22nd European Congress of Endocrinology. Endocrine Abstracts, 70(1). doi: 10.1530/endoabs.70. AEP311

Lopes, G. G. C., Pullig, E. de A., Netto, G. P. M., Matos, I. C., Ribeiro, J. M., & de Oliveira, A. M. (2020). Liraglutida e outros análogos do glp-1: nova perspectiva no tratamento do sobrepeso e obesidade. Revista Atenas Higeia, 2(3), 36 - 42.

Mann, J., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., Buse, J. B., & LEADER Steering Committee and Investigators (2017). Liraglutide and Renal Outcomes in Type 2 Diabetes. The New England journal of medicine, 377(9), 839–848. https://doi.org/10.1056/NEJMoa1616011

Mapa da Obesidade. (2019, December 4). Abeso. https://abeso.org.br/obesidade-e-sindrome-metabolica/mapa-da-obesidade

Marso, S. P., Baeres, F., Bain, S.C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R.E., Thomsen, A.B., Buse, J.B., & LEADER Trial Investigators (2020). Efeitos da liraglutida em desfechos cardiovasculares em pacientes com diabetes com ou sem insuficiência cardíaca. Revista do Colégio Americano de Cardiologia, 75(10), 1128–1141. https://doi.org/10.1016/j.jacc.2019.12.063

Min, M., Ruan, X., Gu, M., & Mueck, A. O. (2019). A prospective randomized comparative study of comprehensive intervention using Orlistat to reduce visceral fat of overweight or obese PCOS patients. Maturitas, 124(2019), 180. https://doi.org/10.1016/j.maturitas.2019.04.181

Nguyen, N. N., Kolobova, I., Wolfe, B. M., & Purnell, J. Q. (2020). Short-term intestinal lipase inhibition in normal-weight individuals does not affect postprandial peptide YY3-36 and glucagon-like peptide-1 levels, hunger or satiety. Diabetes, Obesity and Metabolism, 22(12), 2499–2503. https://doi.org/10.1111/dom.14182

NOVO NORDISK. (2019). Saxenda ® liraglutida. 1–27. https://www.novonordisk.com.br/content/dam/brazil/affiliate/www-novonordisk-br/Profissionais_da_Saude/Bulas-profissionais-de-saude/Saxenda_Bula_Profissional.pdf

Patni, N., Quittner, C., & Garg, A. (2018). Orlistat Therapy for Children With Type 1 Hyperlipoproteinemia: A Randomized Clinical Trial. J Clin Endocrinol Metab, 103, 2403–2407. https://doi.org/10.1210/jc.2018-00369

Philip, W., & James, T. (2005). The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. European Heart Journal Supplements, 7, 44–48. https://doi.org/10.1093/eurheartj/sui086

Resolution of the Collegiate Board - RCB No. 13. It provides for the updating of Annex I, Lists of Narcotic Substances, Psychotropic Substances, Precursors and Others under Special Control, ordinance SVS/MS no. 344, of May 12, 1998 and provides other measures. Brasília, Brazil, March 26, 2010. Recovered from https://is.gd/RJxPdD

Ruan, X., Song, J., Gu, M., Wang, L., Wang, H., & Mueck, A. O. (2018). Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics, 297(6), 1557–1563. https://doi.org/10.1007/s00404-018-4762-0

Salehpour, S., Hosseini, S., Nazari, L., Saharkhiz, N., & Zademodarres, S. (2018). Effects of orlistat on serum androgen levels among iranian obeswomen with polycystic ovarian syndrome. Jornal Brasileiro de Reproducao Assistida, 22(3), 180–184. https://doi.org/10.5935/1518-0557.20180033

SANTOS, J. S. (2018). Avaliar o uso de Liraglutida na redução de peso em pessoas diabéticas e não diabéticas. Revista Especialize On-Line IPOG, Ano 9(15), 1–14.

Shupenina, E. Y., Yushchuk, E. N., Vasyuk, Y. A., Yureneva, S. V., & Dubrovina, A. V. (2019). The experience of sibutramine administration in patients with obesity and controlled arterial hypertension. Obesity and Metabolism, 16(2), 42–48. https://doi.org/10.14341/omet9789

Tamborlane, W. V., Barrientos-Pérez, M., Fainberg, U., Frimer-Larsen, H., Hafez, M., Hale, P. M., Jalaludin, M. Y., Kovarenko, M., Libman, I., Lynch, J. L., Rao, P., Shehadeh, N., Turan, S., Weghuber, D., Barrett, T., & Ellipse Trial Investigators (2019). Liraglutide in Children and Adolescents with Type 2 Diabetes. The New England journal of medicine, 381(7), 637–646. https://doi.org/10.1056/NEJMoa1903822

Vigilância de Fatores De Risco e Proteção Para Doenças Crônicas por Inquérito Telefônico (VIGITEL). (2020). Vigitel Brasil 2019. In Vigitel Brasil 2019: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico: estimativas sobre frequência e distribuição sociodemográfica de fatores de risco e proteção para doenças crônicas nas capitais dos 26 estados. https://bvsms.saude.gov.br/bvs/publicacoes/vigitel_brasil_2019_vigilancia_fatores_risco.pdf

World Health Organization (WHO). (2000). Obesity: Preventing and Managing the Global Epidemic (WHO Technical Report Series). World Health Organization.

Ye, J., Wu, Y., Li, F., Wu, T., Shao, C., Lin, Y., Wang, W., Feng, S., & Zhong, B. (2019). Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Therapeutic Advances in Gastroenterology, 12. https://doi.org/10.1177/1756284819879047

Published

12/03/2022

How to Cite

MARCON, G. M. .; SANCHES, A. C. C. .; VIRTUOSO, S. . Updates of the drugs of the Brazilian Obesity Guideline: a literature review. Research, Society and Development, [S. l.], v. 11, n. 4, p. e10211427139, 2022. DOI: 10.33448/rsd-v11i4.27139. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/27139. Acesso em: 14 nov. 2024.

Issue

Section

Review Article